Clinical trials: Human Papillomavirus Vaccines
Cervical Intraepithelial Neoplasia, Cervical Cancer
A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
This is a bridging trial of the recombinant HPV 16/18 bivalent vaccine manufactured by Xiamen Innovax Biotech CO., LTD.The primary objective of this study is to evaluate the immunogenicity (type specific IgG antibody) and safety…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT02562508
- Testing
- 3 doses of HPV 16/18 bivalent vaccine, 2 doses of HPV 16/18 bivalent vaccine
- Where
- China
- Volunteers
- 979 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Cervical Intraepithelial Neoplasia
DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2
To establish therapeutic dendritic cell (DC) vaccines targeting HPV 16/18 E6/E7 protein to block the progression of CIN1/CIN2 to cervical cancer and evaluate the safety and efficacy of the vaccines.
- Trial name
- NCT03870113
- Testing
- Vaccinated group
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shenzhen People's Hospital
Human Papilloma Virus, HPV-Related Carcinoma
A Tailored, Health Communication Intervention for HPV Vaccine Hesitant Families
The human papillomavirus (HPV) causes 90% of cervical cancers and is implicated in multiple other cancers. The HPV vaccine can prevent the vast majority of these cancers, but it is underused in adolescents, especially among those…
- Conditions
- Human Papilloma Virus, HPV-Related Carcinoma, Vaccine Refusal, Parents
- Trial name
- NCT04380623
- Testing
- Mobile Phone-Based Web-Page: HPV vaccine
- Where
- United States
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Meharry Medical College
Cervical Cancer, Vulvar Cancer
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04425291
- Testing
- 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL®
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Vaccine Effectiveness, HPV Vaccination
A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia
The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months…
- Conditions
- Vaccine Effectiveness, HPV Vaccination, Single Dose, Immunogenicity
- Trial name
- CervALONE (NCT07256912)
- Testing
- quadrivalent HPV vaccine
- Where
- Zambia
- Volunteers
- 1,266 people, healthy volunteers welcome
- Sponsor
- International Agency for Research on Cancer
Cervical Intraepithelial Neoplasia 3
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
This study is to follow up on the change of immune response by measuring HPV type 16/18 E6 and E7 specific T cell response and lesion condition in subjects who have administered in DNA-based therapeutic vaccine.
- Trial name
- GX-188E (NCT02411019)
- Testing
- GX-188E
- Where
- South Korea
- Volunteers
- 67 people
- Sponsor
- Genexine, Inc.
Human Papilloma Virus
PreTeenVax Evaluation
The primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion toolkit implemented in the pediatric healthcare setting on increasing the likelihood that adolescents in…
- Trial name
- NCT03186430
- Testing
- Comprehensive Vaccine Promotion Package
- Where
- 6 sites in United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Emory University
Atypical Squamous Cells of Undetermined Significance, Cervical Cancer
SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells
This randomized phase II trial is studying how well SGN-00101 vaccine works compared to a placebo in treating human papillomavirus and preventing cervical cancer in patients with abnormal cervical cells.
- Conditions
- Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
- Trial name
- NCT00091130
- Testing
- HspE7, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Papillomavirus Infections
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India.
- Trial name
- NCT00380367
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is…
- Trial name
- NCT00652938
- Testing
- HPV Vaccine (GSK580299) Cervarix TM, Engerix B
- Where
- 7 sites in Netherlands, Sweden
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV-Related Squamous Cell Carcinoma
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 \& HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts…
- Trial name
- NCT04180215
- Testing
- HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab.
- Where
- 34 sites in United States, Netherlands and 1 more
- Volunteers
- 198 people
- Sponsor
- Hookipa Biotech GmbH
Human Papilloma Virus Vaccines, Attitude to Health
An Evaluation of Tailored Messages to Address Parental Questions About HPV Vaccination
The purpose of this study is to investigate mother's attitudes about vaccinating their 11-14 year old children against the human papillomavirus (HPV).
- Trial name
- NCT03628885
- Testing
- Top Concern Tailored Intervention, All Concerns Tailored Intervention
- Where
- United States
- Volunteers
- 908 people, healthy volunteers welcome
- Sponsor
- Indiana University
Cervical Cancer
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
The primary objective of the study is to estimate the clinical benefit of cemiplimab + ISA101b after progression on first line chemotherapy, as assessed by objective response rate (ORR).
- Trial name
- NCT04646005
- Testing
- Cemiplimab, ISA101b
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 113 people
- Sponsor
- Regeneron Pharmaceuticals
Genital Warts
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
This study is designed to demonstrate non-inferior immunogenicity of 3 doses of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) in Chinese males 9 through 19 years of age, and 2 doses of the 9vHPV vaccine in…
- Trial name
- NCT05314023
- Testing
- 9vHPV vaccine
- Where
- 5 sites in China
- Volunteers
- 1,590 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus Vaccines
Immunogenicity and Safety of One Dose of HPV Vaccine
This study will assess the immunogenicity and safety of one dose of Cecolin and one dose of Gardasil
- Trial name
- NCT06345885
- Testing
- HPV vaccine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Infections, Papillomavirus
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
This study is intended to provide up to a maximum of four years of annual oncogenic human papillomavirus (HPV) DNA testing and cervical cytology examination for NCT00294047 study subjects who displayed normal cervical cytology…
- Trial name
- NCT01190176
- Testing
- Gynaecological follow-up, Cervarix
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection, HPV
Human Papillomavirus in Young People Epidemiological Research 3
Anal cancer is overrepresented among gay, bisexual and other men who have sex with men (MSM), particularly those living with HIV.
- Conditions
- Human Papillomavirus Infection, HPV, HPV Infection, Anal Cancer
- Trial name
- HYPER3 (NCT05587725)
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Monash University
Infections, Papillomavirus
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
The purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases (AIDs) following females who have received at the least the first dose of Cervarix® as part of their routine health care.
- Trial name
- NCT01153906
- Testing
- Data collection
- Where
- United States
- Volunteers
- 1,516 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Health Services Research
The Efficacy of Digital Educational Interventions on Parental HPV Knowledge and Attitude, and Their Children's Vaccination Rates
The goal of this clinical trial is to examine in the parental HPV knowledge and attitude, and their children's completion rates in Indonesia.
- Trial name
- NCT06341738
- Testing
- Video education about HPV and HPV vaccine, Electronic reminder messages, Usual Information Service
- Where
- Indonesia
- Volunteers
- 374 people
- Sponsor
- Kaohsiung Medical University
Human Papillomavirus (HPV) Vaccines
Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
Human papillomavirus (HPV) vaccines have potential to prevent an average of 26,900 cancer cases each year in the United States, but vaccine coverage rates remain low.
- Trial name
- NCT03429413
- Testing
- Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone
- Where
- United States
- Volunteers
- 1,296 people, healthy volunteers welcome
- Sponsor
- University of Florida